Edwards Lifesciences Co. (NYSE:EW) Shares Bought by Headlands Technologies LLC

Headlands Technologies LLC increased its holdings in Edwards Lifesciences Co. (NYSE:EW) by 115.4% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 5,362 shares of the medical research company’s stock after buying an additional 2,873 shares during the period. Headlands Technologies LLC’s holdings in Edwards Lifesciences were worth $409,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of EW. Turtle Creek Wealth Advisors LLC acquired a new position in shares of Edwards Lifesciences in the 4th quarter valued at about $34,000. Operose Advisors LLC lifted its position in Edwards Lifesciences by 247.0% in the 3rd quarter. Operose Advisors LLC now owns 635 shares of the medical research company’s stock valued at $44,000 after purchasing an additional 452 shares during the last quarter. SRS Capital Advisors Inc. lifted its position in Edwards Lifesciences by 292.6% in the 3rd quarter. SRS Capital Advisors Inc. now owns 636 shares of the medical research company’s stock valued at $44,000 after purchasing an additional 474 shares during the last quarter. NBC Securities Inc. bought a new stake in Edwards Lifesciences in the 3rd quarter valued at about $52,000. Finally, ORG Partners LLC bought a new stake in Edwards Lifesciences in the 3rd quarter valued at about $66,000. 79.46% of the stock is owned by institutional investors and hedge funds.

Edwards Lifesciences Trading Down 1.8 %

Shares of Edwards Lifesciences stock traded down $1.58 during trading on Friday, hitting $86.43. The stock had a trading volume of 4,979,943 shares, compared to its average volume of 2,883,164. The stock has a 50 day simple moving average of $90.28 and a 200 day simple moving average of $78.85. The company has a market capitalization of $52.02 billion, a PE ratio of 37.25, a P/E/G ratio of 4.36 and a beta of 1.05. The company has a quick ratio of 2.40, a current ratio of 3.38 and a debt-to-equity ratio of 0.09. Edwards Lifesciences Co. has a 1 year low of $60.57 and a 1 year high of $96.12.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, April 25th. The medical research company reported $0.66 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.02. The business had revenue of $1.60 billion for the quarter, compared to the consensus estimate of $1.58 billion. Edwards Lifesciences had a net margin of 23.01% and a return on equity of 23.34%. On average, research analysts expect that Edwards Lifesciences Co. will post 2.76 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

EW has been the topic of several recent research reports. Evercore ISI cut their price objective on shares of Edwards Lifesciences from $92.00 to $89.00 and set an “in-line” rating on the stock in a research report on Friday. OTR Global upgraded shares of Edwards Lifesciences from a “mixed” rating to a “positive” rating in a research report on Tuesday, March 26th. Piper Sandler boosted their price target on shares of Edwards Lifesciences from $85.00 to $88.00 and gave the stock a “neutral” rating in a research report on Friday. Oppenheimer boosted their price target on shares of Edwards Lifesciences from $93.00 to $100.00 and gave the stock an “outperform” rating in a research report on Monday, March 18th. Finally, Mizuho boosted their price target on shares of Edwards Lifesciences from $95.00 to $105.00 and gave the stock a “buy” rating in a research report on Thursday, April 11th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and ten have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Edwards Lifesciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $93.33.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 7,255 shares of the company’s stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $94.89, for a total value of $688,426.95. Following the transaction, the chief financial officer now owns 19,074 shares in the company, valued at approximately $1,809,931.86. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other Edwards Lifesciences news, VP Daniel J. Lippis sold 1,715 shares of the company’s stock in a transaction that occurred on Thursday, March 7th. The shares were sold at an average price of $90.98, for a total value of $156,030.70. Following the transaction, the vice president now owns 17,213 shares in the company, valued at approximately $1,566,038.74. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CFO Scott B. Ullem sold 7,255 shares of the company’s stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $94.89, for a total transaction of $688,426.95. Following the completion of the transaction, the chief financial officer now owns 19,074 shares in the company, valued at approximately $1,809,931.86. The disclosure for this sale can be found here. Insiders have sold a total of 194,004 shares of company stock valued at $17,166,254 over the last ninety days. Corporate insiders own 1.29% of the company’s stock.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.